Drug Innovator Launches Pivotal Cancer Trial Breakthrough
Research Report

1. Steve Sobek wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
2.  This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
3. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for H.C. Wainwright & Co., Corvus Pharmaceuticals Inc., January 2, 2025:

This material is confidential and intended for use by Institutional Accounts as defined in FINRA Rule 4512(c). It may also be privileged or otherwise protected by work product immunity or other legal rules. If you have received it by mistake, please let us know by e-mail reply to [email protected] and delete it from your system; you may not copy this message or disclose its contents to anyone. The integrity and security of this message cannot be guaranteed on the Internet.

Investment Banking Services include, but are not limited to, acting as a manager/co-manager in the underwriting or placement of securities, acting as financial advisor, and/or providing corporate finance or capital markets-related services to a company or one of its affiliates or subsidiaries within the past 12 months.

H.C. Wainwright & Co, LLC (the “Firm”) is a member of FINRA and SIPC and a registered U.S. Broker-Dealer.

I, Sean Lee, Swayampakula Ramakanth, Ph.D., Arthur He, Ph.D., Li Chen, Ph.D. and Douglas MacPherson, Ph.D. , certify that

1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies.

None of the research analysts or the research analyst’s household has a financial interest in the securities of Corvus Pharmaceuticals, Inc. (including, without limitation, any option, right, warrant, future, long or short position).

As of December 31, 2024 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Corvus Pharmaceuticals, Inc..

Neither the research analyst nor the Firm knows or has reason to know of any other material conflict of interest at the time of publication of this research report.

The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services. The firm or its affiliates received compensation from Corvus Pharmaceuticals, Inc. for non-investment banking services in the previous 12 months.The Firm or its affiliates did not receive compensation from Corvus Pharmaceuticals, Inc. for investment banking services within twelve months before, but will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report.

The Firm does not make a market in Corvus Pharmaceuticals, Inc. as of the date of this research report. The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. Past performance is no guarantee of future results. This report is offered for informational purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. This research report is not intended to provide tax advice or to be used to provide tax advice to any person. Electronic versions of H.C. Wainwright & Co., LLC research reports are made available to all clients simultaneously. No part of this report may be reproduced in any form without the expressed permission of H.C. Wainwright & Co., LLC. Additional information available upon request.

H.C. Wainwright & Co., LLC does not provide individually tailored investment advice in research reports. This research report is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this research report.

H.C. Wainwright & Co., LLC’s and its affiliates’ salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed in this research report.

H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report.

The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data on the company, industry or security discussed in the report. All opinions and estimates included in this report constitute the analyst’s judgment as of the date of this report and are subject to change without notice.

Securities and other financial instruments discussed in this research report: may lose value; are not insured by the Federal Deposit Insurance Corporation; and are subject to investment risks, including possible loss of the principal amount invested.

Corvus Pharmaceuticals, Inc. (CRVS:NASDAQ), a clinical-stage biopharmaceutical company developing precision medicines to treat cancers and autoimmune diseases, has the potential to generate hundreds of millions of dollars over the next decade, an H.C. Wainwright & Co. analyst wrote in a January 2 research note.

The California company’s lead product is soquelitinib, a first-in-class ITK-specific inhibitor that is being investigated for the treatment of both T-cell lymphomas and atopic dermatitis (AD).

"Beyond these, we believe soquelitinib has potential in a variety of other disorders such as psoriasis, inflammatory bowel disease, and allergic asthma as well," wrote Analyst Sean Lee, who initiated coverage of the stock with a Buy rating and a US$11 per share price target. "Considering just the first two lead indications, we project soquelitinib to generate risk-adjusted revenues of US$801 million by 2034, including US$206 million from cancer and US$595 million from AD."

Lee continued, "Our bullish view on Corvus Pharmaceuticals is based on our positive perception of the following factors: (1) ITK is a promising target implicated in a wide variety of diseases; (2) soquelitinib is a first-in-class ITK inhibitor with a straightforward path to market; (3) additional indications with blockbuster potential; and (4) ciforadenant and mupadolimab provide additional opportunities."

Possible Approval Expected by 2027

Based on positive Phase 1b study results, Corvus initiated a pivotal Phase 3 study of soquelitinib for the treatment of relapsed/refractory peripheral T-cell lymphoma and other T cell lymphomas in October 2024, "which we believe could serve as a convincing proof-of-concept for ITK," Lee wrote.

A total of 150 patients randomized 1:1 to either soquelitinib monotherapy or standard of care chemotherapy of either belinostat or pralatrexate are expected to enroll in the study.

"We currently expect the company to report topline results from this Phase 3 study by mid-2026, and if successful, we believe soquelitinib could be approved in the U.S. as early as 2027," Lee wrote. "Furthermore, the company is also conducting a Phase 1 study of soquelitinib in AD, a more commercially significant indication, and is expected to report topline results before mid-2025."

The analyst said Corvus is also expected to initiate a Phase 1 study of the drug for solid tumors in the first quarter of this year, with initial results expected by the end of the year.

2 Other Drug Candidates

Corvus is also developing two other drug candidates across multiple indications: ciforadenant, an adenosine A2A receptor inhibitor for the treatment of first-line renal cell carcinoma; and mupadolimab, an anti-CD73 antibody, as a treatment for relapsed/refractory non-small cell lung cancer, the analyst wrote.

"We expect the company to report topline results from the ongoing, investigator-led Phase 2 study of ciforadenant in RCC in 2025," he noted. "Currently, we expect ciforadenant and mupadolimab to reach the market in 2030 and 2032, respectively, and generate total risk-adjusted revenues of US$96 million by 2034."

Lee said the price target of US$11 is based on a risk-adjusted net present value (rNPV) analysis of projected future revenues from soquelitinib, ciforadenant, and mupadolimab, assuming an 11% discount rate and a 1% terminal growth rate.

"We derive an rNPV of US$1.2 billion for the products and add in net cash and cash equivalents of US$42 million to arrive at a 12-month price target of US$10.84 per diluted share, which we round to US$11, the analyst wrote.